Which has preferable valuation & earnings, AKTX or GRI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A GRI Bio N/A N/A -$11.96M -$74.16 N/A

Is AKTX or GRI more profitable?

Akari Therapeutics' return on equity of -123.29% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -123.29% -63.01% GRI Bio N/A -199.52% -143.23%

Does the media prefer AKTX or GRI?

In the previous week, Akari Therapeutics had 2 more articles in the media than GRI Bio. MarketBeat recorded 4 mentions for Akari Therapeutics and 2 mentions for GRI Bio. Akari Therapeutics' average media sentiment score of 1.04 beat GRI Bio's score of 0.94 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GRI or GDTC?

GRI Bio presently has a consensus target price of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, GRI or GDTC?

CytoMed Therapeutics has higher revenue and earnings than GRI Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A CytoMed Therapeutics $250K 48.27 -$3.10M N/A N/A

Is GRI or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% CytoMed Therapeutics N/A N/A N/A

Does the media favor GRI or GDTC?

In the previous week, GRI Bio and GRI Bio both had 2 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.40 beat GRI Bio's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GRI or CALC?

CalciMedica is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is GRI or CALC more profitable?

GRI Bio's return on equity of -199.52% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% CalciMedica N/A -863.40% -144.33%

Does the media favor GRI or CALC?

In the previous week, CalciMedica had 4 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.94 beat CalciMedica's score of 0.29 indicating that GRI Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BFRG or GRI?

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, BFRG or GRI?

Bullfrog AI has higher revenue and earnings than GRI Bio. Bullfrog AI is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $120K 101.18 -$6.50M -$0.54 N/A GRI Bio N/A N/A -$11.96M -$74.16 N/A

Is BFRG or GRI more profitable?

GRI Bio's return on equity of -199.52% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% GRI Bio N/A -199.52% -143.23%

Does the media prefer BFRG or GRI?

In the previous week, Bullfrog AI and Bullfrog AI both had 2 articles in the media. GRI Bio's average media sentiment score of 0.94 beat Bullfrog AI's score of 0.87 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PHIO or GRI?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A GRI Bio N/A N/A -$11.96M -$74.16 N/A

Is PHIO or GRI more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% GRI Bio N/A -199.52% -143.23%

Does the media refer more to PHIO or GRI?

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 2 articles in the media. GRI Bio's average media sentiment score of 0.94 beat Phio Pharmaceuticals' score of 0.14 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GRI Bio (GRI) Competitors

$1.82 -0.14 (-7.14%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.06 (+3.35%)

As of 06/26/2026 07:52 PM Eastern

Compare

GRI vs. AKTX, GDTC, CALC, BFRG, and PHIO

Should you buy GRI Bio stock or one of its competitors? MarketBeat compares GRI Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GRI Bio include Akari Therapeutics (AKTX), CytoMed Therapeutics (GDTC), CalciMedica (CALC), Bullfrog AI (BFRG), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry.

How does GRI Bio compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Akari Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.17, meaning that its stock price is 217% less volatile than the broader market.

Akari Therapeutics' return on equity of -123.29% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-123.29%	-63.01%
GRI Bio	N/A	-199.52%	-143.23%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Akari Therapeutics had 2 more articles in the media than GRI Bio. MarketBeat recorded 4 mentions for Akari Therapeutics and 2 mentions for GRI Bio. Akari Therapeutics' average media sentiment score of 1.04 beat GRI Bio's score of 0.94 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akari Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akari Therapeutics currently has a consensus target price of $89.00, suggesting a potential upside of 738.04%. GRI Bio has a consensus target price of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's higher probable upside, analysts plainly believe GRI Bio is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Akari Therapeutics beats GRI Bio on 8 of the 11 factors compared between the two stocks.

How does GRI Bio compare to CytoMed Therapeutics?

GRI Bio (NASDAQ:GRI) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

CytoMed Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
CytoMed Therapeutics	N/A	N/A	N/A

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, GRI Bio and GRI Bio both had 2 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.40 beat GRI Bio's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GRI Bio has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

CytoMed Therapeutics has higher revenue and earnings than GRI Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
CytoMed Therapeutics	$250K	48.27	-$3.10M	N/A	N/A

GRI Bio presently has a consensus target price of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CytoMed Therapeutics beats GRI Bio on 6 of the 11 factors compared between the two stocks.

How does GRI Bio compare to CalciMedica?

GRI Bio (NASDAQ:GRI) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

CalciMedica is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

GRI Bio's return on equity of -199.52% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
CalciMedica	N/A	-863.40%	-144.33%

34.0% of GRI Bio shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GRI Bio has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, CalciMedica had 4 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for CalciMedica and 2 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.94 beat CalciMedica's score of 0.29 indicating that GRI Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GRI Bio presently has a consensus target price of $32.00, suggesting a potential upside of 1,658.24%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,125.64%. Given GRI Bio's higher possible upside, equities analysts clearly believe GRI Bio is more favorable than CalciMedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

GRI Bio beats CalciMedica on 7 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Bullfrog AI has a beta of -2.89, meaning that its stock price is 389% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.17, meaning that its stock price is 217% less volatile than the broader market.

GRI Bio's return on equity of -199.52% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
GRI Bio	N/A	-199.52%	-143.23%

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bullfrog AI and Bullfrog AI both had 2 articles in the media. GRI Bio's average media sentiment score of 0.94 beat Bullfrog AI's score of 0.87 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bullfrog AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bullfrog AI has higher revenue and earnings than GRI Bio. Bullfrog AI is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	101.18	-$6.50M	-$0.54	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 8.7% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

GRI Bio beats Bullfrog AI on 9 of the 13 factors compared between the two stocks.

How does GRI Bio compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,343.30%. GRI Bio has a consensus target price of $32.00, suggesting a potential upside of 1,658.24%. Given GRI Bio's higher probable upside, analysts clearly believe GRI Bio is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals' return on equity of -77.34% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
GRI Bio	N/A	-199.52%	-143.23%

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 2 articles in the media. GRI Bio's average media sentiment score of 0.94 beat Phio Pharmaceuticals' score of 0.14 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 8.7% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market.

Summary

Phio Pharmaceuticals beats GRI Bio on 6 of the 10 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.47M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.12%
P/E Ratio	-0.02	21.56	25.76	24.17
Price / Sales	N/A	335.66	556.43	98.84
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	0.44	8.34	10.77	6.35
Net Income	-$11.96M	$23.91M	$3.57B	$337.63M
7 Day Performance	-3.09%	3.38%	2.15%	0.06%
1 Month Performance	-13.33%	1.51%	1.06%	-0.15%
1 Year Performance	-94.88%	65.14%	34.16%	27.55%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	2.4568 of 5 stars	$1.82 -7.1%	$32.00 +1,658.2%	-94.9%	$3.47M	N/A	N/A	1	News Coverage Gap Down
AKTX Akari Therapeutics	3.4982 of 5 stars	$11.79 +5.0%	$89.00 +654.9%	-77.3%	$12.85M	N/A	N/A	9	News Coverage Positive News Analyst Upgrade Short Interest Decrease Gap Up
GDTC CytoMed Therapeutics	1.4837 of 5 stars	$1.07 -0.9%	N/A	-55.2%	$12.78M	$250K	N/A	N/A	Positive News Gap Down
CALC CalciMedica	1.801 of 5 stars	$0.80 +2.8%	$10.00 +1,144.9%	-42.9%	$12.34M	N/A	N/A	30	News Coverage Short Interest Increase Gap Up
BFRG Bullfrog AI	0.9111 of 5 stars	$0.66 +0.3%	N/A	-58.3%	$12.24M	$120K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. AKTX, GDTC, CALC, BFRG, and PHIO

How does GRI Bio compare to Akari Therapeutics?

Summary

How does GRI Bio compare to CytoMed Therapeutics?

Summary

How does GRI Bio compare to CalciMedica?

Summary

How does GRI Bio compare to Bullfrog AI?

Summary

How does GRI Bio compare to Phio Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. AKTX, GDTC, CALC, BFRG, and PHIO

How does GRI Bio compare to Akari Therapeutics?

Which has more risk and volatility, AKTX or GRI?

Is AKTX or GRI more profitable?

Which has preferable valuation & earnings, AKTX or GRI?

Do insiders and institutionals hold more shares of AKTX or GRI?

Does the media prefer AKTX or GRI?

Do analysts rate AKTX or GRI?

Summary

How does GRI Bio compare to CytoMed Therapeutics?

Is GRI or GDTC more profitable?

Do institutionals and insiders hold more shares of GRI or GDTC?

Does the media favor GRI or GDTC?

Which has more volatility & risk, GRI or GDTC?

Which has better valuation and earnings, GRI or GDTC?

Do analysts recommend GRI or GDTC?

Summary

How does GRI Bio compare to CalciMedica?

Which has preferable valuation & earnings, GRI or CALC?

Is GRI or CALC more profitable?

Do institutionals and insiders hold more shares of GRI or CALC?

Which has more volatility and risk, GRI or CALC?

Does the media favor GRI or CALC?

Do analysts recommend GRI or CALC?

Summary

How does GRI Bio compare to Bullfrog AI?

Which has more volatility & risk, BFRG or GRI?

Is BFRG or GRI more profitable?

Do analysts recommend BFRG or GRI?

Does the media prefer BFRG or GRI?

Which has higher earnings and valuation, BFRG or GRI?

Do institutionals & insiders hold more shares of BFRG or GRI?

Summary

How does GRI Bio compare to Phio Pharmaceuticals?

Which has preferable earnings & valuation, PHIO or GRI?

Do analysts rate PHIO or GRI?

Is PHIO or GRI more profitable?

Does the media refer more to PHIO or GRI?

Do insiders & institutionals have more ownership in PHIO or GRI?

Which has more volatility & risk, PHIO or GRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools